Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-10-10
2006-10-10
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S363000, C540S364000
Reexamination Certificate
active
07119083
ABSTRACT:
Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1areceptor.
REFERENCES:
patent: 5759865 (1998-06-01), Bruns et al.
patent: 6204260 (2001-03-01), Bruns, Jr. et al.
patent: 6627625 (2003-09-01), Koppel
patent: WO 97/30707 (1997-08-01), None
Hirai et al, “An Example of the β-Lactam Ring Formation and Novel Pyrrolinoazetidinone Ring Construction”,Sankyo Kenyusho Nempo, vol. 37, pp. 133-139, (1985).
Ojima et al., “Asymmetric Alkylations of a Phenylalanylglycinate Equivalent. New routes to Dipeptides BEaring α-Alkyl-α-amino Acid Residues”,J. Amer. Chem. Soc., vol. 122, pp. 770-774, (1990).
Bruns, Jr. Robert F.
Guillon Christophe D. G.
Heindel Ned D.
Koppel Gary A.
Miller Marvin J.
Azevan Pharmaceuticals, Inc.
Barnes & Thornburg LLP
Berch Mark L.
LandOfFree
β-Lactamyl vasopressin V 1a Antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with β-Lactamyl vasopressin V 1a Antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and β-Lactamyl vasopressin V 1a Antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3717805